Zealand Pharma A/S (22Z.BE)
| Previous close | 81.35 |
| Open | 81.65 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 80.45 - 84.25 |
| 52-week range | 28.48 - 102.30 |
| Volume | |
| Avg. volume | 66 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean weight loss of up to 4.3% after 12 weeks with low doses of dapiglutide treatment Dapiglutide was assessed to be well-toleratedTolerability profile observed suggests doses investigated were at the lower end of the therapeutic rangeMuch higher doses of dapiglutide are being investigated in the ongoing 13
- GlobeNewswire
Zealand Pharma Announces Financial Results for the First Quarter of 2024
Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data read-outs across differentiated obesity assets in the second quarter. Strong topline results announced in Boehringer Ingelheim Phase 2 clinical trial for survodutide in MASHPDUFA date for glepaglutide in SBS set by US FDA for December 22, 2024 PDUFA date for dasiglucagon in CHI for up to three weeks of dosi
- GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 25 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by per
